AKTX 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-13

• ● more effective cancer-killing properties, or cytotoxicity;

• ● robust activation of the immune system to drive greater and more enduring efficacy in treating cancer sustained duration of response of tumor regression or elimination;

• ● ability to be used in combination with checkpoint inhibitors to potentially deliver synergistic efficacy results (more than additive) to drive potential longer-term cancer remissions;

• ● reduced tumor resistance leading to superior outcomes; and

• ● improved safety and tolerability relative to ADCs that are currently available.

相对上期删除的文字 · 来源:10-Q · 2026-05-19

• ●robust activation of the immune system to drive greater and more enduring efficacy in treating cancer sustained duration of response of tumor regression or elimination;

• ●ability to be used in combination with checkpoint inhibitors to potentially deliver synergistic efficacy results (more than additive) to drive potential longer-term cancer remissions;

• ●improved safety and tolerability relative to ADCs that are currently available.

• On March 31, 2026, we completed our previously announced 2026 ADS Ratio Change, which changed the ratio of our ADSs to ordinary shares to a new ratio of one ADS representing 80,000 ordinary shares.

• During the three months ended March 31, 2026, our loss from operations increased by $12.2 million, as compared to the three months ended March 31, 2025, which was primarily due to a $12.1 million non-cash impairment on other intangible assets and goodwill. Our total operating expenses are set forth …